Bipolar Disorder Clinical Trials in New York

View 13 new treatments for Bipolar Disorder in New York, NY near me. Every day, Power helps hundreds of Bipolar Disorder patients connect with leading medical research.
View 14 trials in New York
Filter (14)

IM Ketamine vs Midazolam for Suicidal Thoughts

Research Clinic, New York + 1 more

This trial tests whether a shot of ketamine can quickly reduce suicidal thoughts in depressed adults who visit the emergency room. These patients are at high risk of suicide and need fast-acting treatment. Ketamine works by quickly changing brain chemicals to improve mood and reduce suicidal thoughts. It has been found to rapidly reduce depressive symptoms and suicidal thoughts, making it a potential fast-acting treatment for suicidality.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 4 - 6 Weeks
Michael Grunebaum, MD
Principal Investigator

Multiple Medications for Bipolar Depression

Research Clinic, New York + 2 more

This trial is testing four different medications to find the best treatment for adults with bipolar disorder type 1 who are currently depressed. The medications work by balancing brain chemicals that affect mood. The goal is to help patients recover from depression and stay well.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Olanzapine-samidorphan + Exercise for Bipolar Disorder

Research Clinic, New York + 1 more

This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic exercise.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Cariprazine for Bipolar Disorder

Research Clinic, New York + 1 more

This trial will use cariprazine (Vraylar) to treat individuals with bipolar depression who are not currently on medication. Researchers will use brain scans to understand how the medication affects the brain. The goal is to improve treatment options for those who do not respond well to current medications.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 5 - 8 Weeks
Martin Lan, MD
Principal Investigator

Lumateperone for Bipolar Mania

Intra-Cellular Therapies Clinic, Glen Oaks + 1 more

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

BHV-7000 for Bipolar Disorder

Biohaven Clinic, Staten Island + 1 more

The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
Waitlist
Phase 2 & 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

BHV-7000 for Bipolar Disorder

Biohaven Clinic, Staten Island + 1 more

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.
Waitlist

No Placebo Trial

Phase 2
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

ABBV-932 for Bipolar Disorder

AbbVie Clinic, Cedarhurst + 1 more

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Study doctors put participants in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 adult participants with bipolar I or II disorder will be enrolled in approximately 40 sites worldwide. Participants will receive oral capsules of ABBV-932 or matching placebo once daily for 6 weeks. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Recruiting
Phase 2
Est. 3 - 6 Weeks
ABBVIE INC.
Study Director

NMRA-335140 for Bipolar Depression

Neumora Clinic, Brooklyn + 2 more

This trial is testing a new medication called NMRA-335140 to see if it can help adults with Bipolar II disorder who are experiencing major depression. The medication aims to improve mood and reduce feelings of depression.Show More
Recruiting
Phase 2
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Affective Awareness for Suicide Prevention

Research Clinic, Bronx + 1 more

This trial tests a new approach to help veterans with serious mental illness who are at risk of suicide. The treatment combines group education sessions and a smartphone app to improve emotional awareness and social functioning. By helping veterans understand their emotions better, the goal is to reduce their suicide risk.Show More
Recruiting

No Placebo Trial

Phase 1
Est. 6 - 12 Weeks
David Kimhy, PhD
Principal Investigator
Page 1 of 2

Frequently Asked Questions

How much do bipolar clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do bipolar clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across bipolar trials in New York, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for bipolar patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

What promising new drugs are being tested?

In New York, research for bipolar disorder includes treatments like NMDA receptor antagonists and Vagus Nerve Stimulation. Specific interventions being studied are Ketamine hydrochloride injection, Midazolam injection, and the VNS Therapy® System.